Research Summary

Analyzed using Evidence Intelligence™

GABA shows no beta-cell regeneration in type 1 diabetes

Last updated September 9, 2026

Key finding

No effect on fasting C-peptide levels were identified during the course of study.

This study investigated the effects of GABA on beta-cell regeneration in adults with long-standing type 1 diabetes, finding no significant improvements in key outcomes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study investigated the effects of GABA on beta-cell regeneration in adults with long-standing type 1 diabetes, finding no significant improvements in key outcomes.

Clinical relevance

Understanding the effectiveness of potential therapies like GABA is crucial for developing new treatments for type 1 diabetes. The lack of positive results highlights the challenges in finding effective interventions for long-standing diabetes and informs future research directions.

Keep in mind

The study had a small sample size, limiting generalizability. No significant effects were observed, indicating unclear effectiveness. Participants experienced treatment-related adverse effects.

Published in

Journal Reference

Publication details and source links for this paper.

Henrik H, Per L, Georgios T, Bryndis B, Daniel E, Per-Ola C. Gamma-amino butyric acid (GABA) as a potential beta-cell regenerative therapy in adults with long-standing type 1 diabetes. Scientific Reports. 2025;15:11530. doi:10.1038/s41598-025-95751-y

View DOI View on PubMed View on PMC

Main Effects

No effect on fasting C-peptide levels was identified.

No effect on stimulated C-peptide levels was identified.

No improvement in HbA1c levels was observed.

Hypoglycemic hormonal counter-regulation was unaltered.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to GABA 200 mg and C-peptide, Counter-regulatory hormone response to hypoglycemia, Elevated liver transaminase, and 2 more.

This study contributes evidence to

Intervention

GABA 200 mg

Outcome

C-peptide

Evidence topic

C-Peptide

Primary intervention

GABA 200 mg

Primary outcomes

C-peptide
Counter-regulatory hormone response to hypoglycemia
Elevated liver transaminase

Evidence topics

C-Peptide HbA1c Reduction

Primary intervention

GABA 200 mg

Primary outcomes

C-peptide Counter-regulatory hormone response to hypoglycemia Elevated liver transaminase

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence topic

C-Peptide

matched_outcome

Related evidence

Evidence topic

HbA1c Reduction

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

C-peptide

GABA 200 mg → C-peptide

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Counter-regulatory hormone response to hypoglycemia

GABA 200 mg → Counter-regulatory hormone response to hypoglycemia

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Elevated liver transaminase

GABA 200 mg → Elevated liver transaminase

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Fasting C-peptide levels

GABA 200 mg → Fasting C-peptide levels

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

HbA1c

GABA 200 mg → HbA1c

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

GABA treatment did not improve fasting or stimulated C-peptide levels.
HbA1c levels remained unchanged across treatment arms.
Two participants discontinued due to elevated liver transaminase levels.

Who this applies to

Adults with long-standing type 1 diabetes.
Participants experiencing challenges in glycemic control.

Keep in Mind

Results may not be applicable to younger populations or those with recent-onset diabetes.
The study did not assess long-term effects beyond the treatment period.
Further research is needed to explore alternative therapies for beta-cell regeneration.

Between the Lines

The study had a small sample size, limiting generalizability.
No significant effects were observed, indicating unclear effectiveness.
Participants experienced treatment-related adverse effects.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GABA 200 mg and C-peptide Levels, GABA 200 mg and Counter-regulatory hormone response to hypoglycemia.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GABA 200 mg → C-peptide Levels

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Medications

Detailed evidence

GABA 200 mg → Counter-regulatory hormone response to hypoglycemia

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

C-peptide Levels Evidence Hub

All studies measuring C-peptide Levels

1 studies

outcome_hub

Measures C-peptide Levels as a key outcome.

Counter-regulatory hormone response to hypoglycemia Evidence Hub

All studies measuring Counter-regulatory hormone response to hypoglycemia

1 studies

outcome_hub

Measures Counter-regulatory hormone response to hypoglycemia as a key outcome.

GABA 200 mg Evidence Hub

All studies on GABA 200 mg

1 studies

intervention_hub

Contributes to GABA 200 mg evidence base.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on GABA 200 mg and C-peptide

Intervention: GABA 200 mgOutcome: C-peptide

1 results

All studies on GABA 200 mg and Counter-regulatory hormone response to hypoglycemia

Intervention: GABA 200 mgOutcome: Counter-regulatory hormone response to hypoglycemia

1 results

All studies on GABA 200 mg

Intervention: GABA 200 mg

1 results

All studies measuring C-peptide

Outcome: C-peptide

1 results

All studies measuring Counter-regulatory hormone response to hypoglycemia

Outcome: Counter-regulatory hormone response to hypoglycemia

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GABA 200 mg improve c-peptide?

Emerging Evidence

Current evidence does not show a clear benefit of GABA 200 mg for c-peptide.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does GABA 200 mg affect counter-regulatory hormone response to hypoglycemia?

Emerging Evidence

Current evidence does not show a clear effect of GABA 200 mg on counter-regulatory hormone response to hypoglycemia.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Counter-regulatory hormone response to hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does GABA 200 mg improve elevated liver transaminase?

Emerging Evidence

Current evidence does not show a clear benefit of GABA 200 mg for elevated liver transaminase.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Elevated liver transaminase
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does GABA 200 mg improve fasting c-peptide levels?

Emerging Evidence

Current evidence does not show a clear benefit of GABA 200 mg for fasting c-peptide levels.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Fasting C-peptide levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

C-Peptide Evidence Hub HbA1c Reduction Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on GABA 200 mg and C-peptide All studies on GABA 200 mg and Counter-regulatory hormone response to hypoglycemia All studies on GABA 200 mg and Fasting C-peptide levels All studies on GABA 200 mg and HbA1c

Related research

Read related research summaries.

HRS-7535 improves glycemic control in adults with type 2 diabetes High-protein diet shows little effect on glycemic control in diabetes Hybrid Closed-Loop Insulin Improves Glycemic Control in Youth QCC Model Enhances Diabetes Management Saxagliptin may maintain beta-cell function in type 1 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.